Please login to the form below

Not currently logged in
Email:
Password:

SMC approves Glivec for GIST

Glivec has been approved for use within NHS Scotland as adjuvant post-surgery therapy to delay the recurrence of GIST

The Scottish Medicines Consortium (SMC) has approved the use of Novartis' imatinib (Glivec/Gleevec) within NHS Scotland for use in the adjuvant treatment of adults who are at a high risk of recurrence following complete resection of Kit (CD117)-positive gastrointestinal stromal tumours (GIST).

The drug advice notes that imatinib, given for a period of one year, significantly improved the estimated one year recurrence-free survival compared with placebo and was associated with an increase of 16.4 months in median time to recurrence in patients at high risk of relapse following resection. The economic case was demonstrated for a one-year adjuvant treatment duration only.

The SMC's decision is in contrast to the National Institute for Health and Clinical Excellence's (NICE) decision to reject the drug for use in England and Wales in August.

NICE stated that although there is evidence that giving imatinib as adjuvant post-surgery therapy can delay the recurrence of GIST, there is a lack of evidence relating to the clinical effectiveness of imatinib, in particular whether adjuvant imatinib extends life expectancy, how long treatment should be continued and whether resistance to imatinib develops.

15th September 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics